DBV Technologies | DBVT - Gross Profit On Sales

Stock Price
20.87
Daily Change
-0.59 -2.75%
Monthly
16.01%
Yearly
406.55%
Q1 Forecast
21.05

DBV Technologies reported $2.77M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amarin USD 22.21M 28.15M Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
DBV Technologies USD 2.77M 33.21M Sep/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Incyte USD 1.27B 130.22M Sep/2025
Insmed USD 111.44M 33.36M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
United Therapeutics USD 602.1M 108.9M Sep/2025